Innoviva(NASDAQ) INVA

Market Cap$1.55B

Since IPO (2004)+56%

5 Year+35%

1 Year+5%

1 Month+1%

$21.48

+1.08%

+0.23Today

After hours$21.49+$0.01 (+0.05%)

Innoviva last closing stock price
Metric	Price	Date
Last close	USD 21.48	2026-08-19

Innoviva stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+3.22%	USD 20.81	2026-08-12
1 month	+0.94%	USD 21.28	2026-07-20
3 month	-3.24%	USD 22.20	2026-05-21
Year to date	+7.45%	USD 19.99	2025-12-31
1 year	+4.68%	USD 20.52	2025-08-19
3 year	+57.48%	USD 13.64	2023-08-18
5 year	+34.76%	USD 15.94	2021-08-20
Since inception	+56.45%	USD 13.58	2004-10-05

Innoviva Financials at a Glance

Market Cap

$1.55B

Revenue (TTM)

$443.43M

Net Income (TTM)

$357.24M

EPS (TTM)

$4.10

P/E Ratio

5.23

Dividend

$0.00

Beta (Volatility)

0.37 (Low)

Dividend

$0.00

Beta (Volatility)

0.37 (Low)

Price

$21.48

Volume

422

Open

$21.45

Price

$21.48

Volume

422

Open

$21.45

Previous Close

$21.48

Daily Range

$21.36 - $21.70

52-Week Range

$16.52 - $25.15

Estimated Earnings Date

Nov 4, 2026

Dividend

$0.00

Beta (Volatility)

0.37 (Low)

Price

$21.48

Volume

422

Open

$21.45

Previous Close

$21.48

Daily Range

$21.36 - $21.70

52-Week Range

$16.52 - $25.15

Estimated Earnings Date

Nov 4, 2026

INVA News

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

Jonathan PoncianoMay 29, 2026

Page 1

INVA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innoviva

Innoviva, Inc. earns royalties from medicines that help people breathe. It also sells specialized treatments for serious hospital-based infections. The company invests in other businesses to create new medical solutions.

Medicines and Medical Portfolios

Respiratory Assets: Royalties from Glaxo Group Limited on medications like RELVAR/BREO ELLIPTA and ANORO ELLIPTA for lung conditions.
Critical Care Products: Hospital-focused treatments such as GIAPREZA for distributive shock and XACDURO for bacterial pneumonia.
Infectious Disease Treatments: Antibiotics including XERAVA for abdominal infections and ZEVTERA for skin and blood infections.
Oral Delivery Platform: LYNX technology designed to turn daily oral medicines into weekly or monthly doses.

Strategic Growth and Expansion

Launched Nortiva Bio in the second quarter of 2026 to advance the LYNX long-acting oral drug delivery platform.
Entered an exclusive agreement with Dr. Reddy's Laboratories in the second quarter of 2026 to commercialize XACDURO in South and Central America.
Commercially launched the antibiotic ZEVTERA in the third quarter of 2025 for treating serious bacterial infections.
Obtained FDA approval for NUZOLVENCE on Dec. 12, 2025, for the treatment of uncomplicated urogenital gonorrhea.

A Differentiated Business Model

Innoviva operates a dual-revenue model that combines steady royalty streams with an active, hospital-focused specialty therapeutics platform. Its disciplined capital allocation strategy involves investing in external healthcare assets, such as Armata Pharmaceuticals, to target significant unmet medical needs.

Performance by the Numbers

Total revenue reached $119.6 million in the second quarter of 2026, up 19% year over year.
Net product sales grew to $51.8 million in the second quarter of 2026, up 46% year over year.
The company reported a net loss of $83.4 million in the second quarter of 2026, primarily due to a $161.0 million drop in the fair value of investments.
Cash and cash equivalents totaled $570.4 million as of June 30, 2026.
Innoviva repurchased 1,403,247 shares for $31.4 million during the second quarter of 2026.

The Evolution of Innoviva

Innoviva has transformed from a pure royalty-based business into a diversified healthcare company with its own operating platform. Its focus on critical care and infectious diseases complements its stable income from respiratory treatment partnerships.

AI Generated • Aug 6, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

159

CEO

Pavel Raifeld, CFA, MBA

Website

www.inva.com

Headquarters

Burlingame, CA 94010, US

INVA Financials

Key Financial Metrics (TTM)

Gross Margin

73.09%

Operating Margin

36.66%

Net Income Margin

80.56%

Return on Equity

30.03%

Return on Capital

11.36%

Return on Assets

20.98%

Earnings Yield

19.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.55B

Shares Outstanding

72.25M

Volume

422

Avg. Volume

833.54K

Financials (TTM)

Gross Profit

$324.09M

Operating Income

$162.58M

EBITDA

$823.34M

Operating Cash Flow

$191.49M

Capital Expenditure

-$3.17M

Free Cash Flow

$188.32M

Cash & ST Invst.

$579.06M

Total Debt

$269.66M

Innoviva Performance Analysis

Innoviva annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 5,508,000	-98.6%
2023	2023-12-31	USD 324,263,000	5787.1%
2024	2024-12-31	USD 372,511,000	14.9%
2025	2025-12-31	USD 425,128,000	14.1%

Innoviva sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	7.5%
Q4	2025-12-31	9.5%
Q1	2026-03-31	-17.0%
Q2	2026-06-30	22.0%

Innoviva annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.08	N/A
2023	2023-12-31	USD 2.20	N/A
2024	2024-12-31	USD 0.36	-83.6%
2025	2025-12-31	USD 3.30	811.7%

Innoviva sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	40.3%
Q4	2025-12-31	79.6%
Q1	2026-03-31	14.4%
Q2	2026-06-30	-151.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$119.59M

+19.3%

Gross Profit

$90.62M

+1.0%

Gross Margin

75.77%

N/A

Market Cap

$1.55B

N/A

Market Cap/Employee

$9.76M

N/A

Employees

159

N/A

Net Income

-$83.42M

-231.0%

EBITDA

$267.22M

+218.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$579.06M

+16.3%

Total Debt

$269.66M

-40.2%

Accounts Receivable

$110.62M

+25.3%

Inventory

$38.97M

-20.5%

Long Term Debt

$268.95M

+4.2%

Short Term Debt

$712.00K

-99.6%

Return on Assets

20.98%

N/A

Return on Invested Capital

9.82%

N/A

Free Cash Flow

$51.54M

+16.9%

Operating Cash Flow

$51.97M

+17.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

INBXInhibrx Biosciences Inc.

INBXInhibrx Biosciences Inc.$101.48+7.25%

SNDXSyndax Pharmaceuticals, Inc.

SNDXSyndax Pharmaceuticals, Inc.$20.77+4.29%

IMTXImmatics N.V.

IMTXImmatics N.V.$9.25+1.76%

CVACCureVac N.V.

CVACCureVac N.V.$4.66+0.00%

NKTRNektar Therapeutics

NKTRNektar Therapeutics$76.08+3.31%

MDXGMiMedx Group, Inc.

MDXGMiMedx Group, Inc.$4.45+2.53%

ATAIAtai Beckley Inc.

ATAIAtai Beckley Inc.$7.36+0.96%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

WBSWebster Financial

WBSWebster Financial$77.57-0.01%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$38.78+0.06%

MRNAModerna

MRNAModerna$174.38+1.77%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$120.74-0.06%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$47.05+0.06%

MSTRStrategy

MSTRStrategy$104.25+0.13%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$15.88+0.10%

Questions About INVA

What is the current price of Innoviva?

Innoviva is trading at $21.48 per share.

What is the 52-week range for Innoviva?

Over the past 52 weeks, Innoviva has traded between $16.52 and $25.15.

How much debt does Innoviva have?

As of the most recent reporting period, Innoviva reported total debt of $269.66M.

How much cash does Innoviva have on hand?

Innoviva reported $570.39M in cash and cash equivalents in its most recent financial results.

What is Innoviva’s dividend yield?

Innoviva does not currently have a dividend yield.

Innoviva(NASDAQ) INVA

Innoviva Financials at a Glance

INVA News

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

Innoviva (INVA) Q2 Sales Jump 64%

3 Small-Cap Stocks With Big-Cap Potential

2 Best Biotech Stocks to Buy in August

2 Incredibly Cheap Biotech Stocks

3 Top Biotech Stocks to Buy in April

3 Under-the-Radar Value Stocks to Buy in 2019

13 of the Cheapest Healthcare Stocks

INVA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Innoviva

Medicines and Medical Portfolios

Strategic Growth and Expansion

A Differentiated Business Model

Performance by the Numbers

The Evolution of Innoviva

INVA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Innoviva Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About INVA

What is the current price of Innoviva?

What is the 52-week range for Innoviva?

How much debt does Innoviva have?

How much cash does Innoviva have on hand?

What is Innoviva’s dividend yield?

Premium Investing Services